Plasmon resonant liposomes for controlled drug delivery

Shellie S. Knights-Mitchell, Marek Romanowski

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Nanotechnology use in drug delivery promotes a reduction in systemic toxicity, improved pharmacokinetics, and better drug bioavailability. Liposomes continue to be extensively researched as drug delivery systems (DDS) with formulations such as Doxil<sup>®</sup> and Ambisome<sup>®</sup> approved by FDA and successfully marketed in the United States. However, the limited ability to precisely control release of active ingredients from these vesicles continues to challenge the broad implementation of this technology. Moreover, the full potential of the carrier to sequester drugs until it can reach its intended target has yet to be realized. Here, we describe a liposomal DDS that releases therapeutic doses of an anticancer drug in response to external stimulus. Earlier, we introduced degradable plasmon resonant liposomes. These constructs, obtained by reducing gold on the liposome surface, facilitate spatial and temporal release of drugs upon laser light illumination that ultimately induces an increase in temperature. In this work, plasmon resonant liposomes have been developed to stably encapsulate and retain doxorubicin at physiological conditions represented by isotonic saline at 37 °C and pH 7.4. Subsequently, they are stimulated to release contents either by a 5 °C increase in temperature or by laser illumination (760 nm and 88 mW/cm<sup>2</sup> power density). Successful development of degradable plasmon resonant liposomes responsive to near-infrared light or moderate hyperthermia can provide a new delivery method for multiple lipophilic and hydrophilic drugs with pharmacokinetic profiles that limit clinical utility.

Original languageEnglish (US)
Title of host publicationProgress in Biomedical Optics and Imaging - Proceedings of SPIE
PublisherSPIE
Volume9338
ISBN (Print)9781628414288
DOIs
StatePublished - 2015
EventColloidal Nanoparticles for Biomedical Applications X - San Francisco, United States
Duration: Feb 7 2015Feb 9 2015

Other

OtherColloidal Nanoparticles for Biomedical Applications X
CountryUnited States
CitySan Francisco
Period2/7/152/9/15

Fingerprint

Controlled drug delivery
Liposomes
delivery
drugs
Pharmacokinetics
Pharmaceutical Preparations
Drug Delivery Systems
Lighting
Lasers
Light
Nanotechnology
Temperature
Drug delivery
Gold
Doxorubicin
illumination
Biological Availability
Toxicity
bioavailability
Fever

Keywords

  • drug delivery
  • Liposomes
  • nanomedicine
  • plasmon resonance

ASJC Scopus subject areas

  • Atomic and Molecular Physics, and Optics
  • Electronic, Optical and Magnetic Materials
  • Biomaterials
  • Radiology Nuclear Medicine and imaging

Cite this

Knights-Mitchell, S. S., & Romanowski, M. (2015). Plasmon resonant liposomes for controlled drug delivery. In Progress in Biomedical Optics and Imaging - Proceedings of SPIE (Vol. 9338). [93381D] SPIE. https://doi.org/10.1117/12.2080485

Plasmon resonant liposomes for controlled drug delivery. / Knights-Mitchell, Shellie S.; Romanowski, Marek.

Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 9338 SPIE, 2015. 93381D.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Knights-Mitchell, SS & Romanowski, M 2015, Plasmon resonant liposomes for controlled drug delivery. in Progress in Biomedical Optics and Imaging - Proceedings of SPIE. vol. 9338, 93381D, SPIE, Colloidal Nanoparticles for Biomedical Applications X, San Francisco, United States, 2/7/15. https://doi.org/10.1117/12.2080485
Knights-Mitchell SS, Romanowski M. Plasmon resonant liposomes for controlled drug delivery. In Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 9338. SPIE. 2015. 93381D https://doi.org/10.1117/12.2080485
Knights-Mitchell, Shellie S. ; Romanowski, Marek. / Plasmon resonant liposomes for controlled drug delivery. Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 9338 SPIE, 2015.
@inproceedings{6359f1f8898c4e91b2db9349afcc0ce0,
title = "Plasmon resonant liposomes for controlled drug delivery",
abstract = "Nanotechnology use in drug delivery promotes a reduction in systemic toxicity, improved pharmacokinetics, and better drug bioavailability. Liposomes continue to be extensively researched as drug delivery systems (DDS) with formulations such as Doxil{\circledR} and Ambisome{\circledR} approved by FDA and successfully marketed in the United States. However, the limited ability to precisely control release of active ingredients from these vesicles continues to challenge the broad implementation of this technology. Moreover, the full potential of the carrier to sequester drugs until it can reach its intended target has yet to be realized. Here, we describe a liposomal DDS that releases therapeutic doses of an anticancer drug in response to external stimulus. Earlier, we introduced degradable plasmon resonant liposomes. These constructs, obtained by reducing gold on the liposome surface, facilitate spatial and temporal release of drugs upon laser light illumination that ultimately induces an increase in temperature. In this work, plasmon resonant liposomes have been developed to stably encapsulate and retain doxorubicin at physiological conditions represented by isotonic saline at 37 °C and pH 7.4. Subsequently, they are stimulated to release contents either by a 5 °C increase in temperature or by laser illumination (760 nm and 88 mW/cm2 power density). Successful development of degradable plasmon resonant liposomes responsive to near-infrared light or moderate hyperthermia can provide a new delivery method for multiple lipophilic and hydrophilic drugs with pharmacokinetic profiles that limit clinical utility.",
keywords = "drug delivery, Liposomes, nanomedicine, plasmon resonance",
author = "Knights-Mitchell, {Shellie S.} and Marek Romanowski",
year = "2015",
doi = "10.1117/12.2080485",
language = "English (US)",
isbn = "9781628414288",
volume = "9338",
booktitle = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",
publisher = "SPIE",

}

TY - GEN

T1 - Plasmon resonant liposomes for controlled drug delivery

AU - Knights-Mitchell, Shellie S.

AU - Romanowski, Marek

PY - 2015

Y1 - 2015

N2 - Nanotechnology use in drug delivery promotes a reduction in systemic toxicity, improved pharmacokinetics, and better drug bioavailability. Liposomes continue to be extensively researched as drug delivery systems (DDS) with formulations such as Doxil® and Ambisome® approved by FDA and successfully marketed in the United States. However, the limited ability to precisely control release of active ingredients from these vesicles continues to challenge the broad implementation of this technology. Moreover, the full potential of the carrier to sequester drugs until it can reach its intended target has yet to be realized. Here, we describe a liposomal DDS that releases therapeutic doses of an anticancer drug in response to external stimulus. Earlier, we introduced degradable plasmon resonant liposomes. These constructs, obtained by reducing gold on the liposome surface, facilitate spatial and temporal release of drugs upon laser light illumination that ultimately induces an increase in temperature. In this work, plasmon resonant liposomes have been developed to stably encapsulate and retain doxorubicin at physiological conditions represented by isotonic saline at 37 °C and pH 7.4. Subsequently, they are stimulated to release contents either by a 5 °C increase in temperature or by laser illumination (760 nm and 88 mW/cm2 power density). Successful development of degradable plasmon resonant liposomes responsive to near-infrared light or moderate hyperthermia can provide a new delivery method for multiple lipophilic and hydrophilic drugs with pharmacokinetic profiles that limit clinical utility.

AB - Nanotechnology use in drug delivery promotes a reduction in systemic toxicity, improved pharmacokinetics, and better drug bioavailability. Liposomes continue to be extensively researched as drug delivery systems (DDS) with formulations such as Doxil® and Ambisome® approved by FDA and successfully marketed in the United States. However, the limited ability to precisely control release of active ingredients from these vesicles continues to challenge the broad implementation of this technology. Moreover, the full potential of the carrier to sequester drugs until it can reach its intended target has yet to be realized. Here, we describe a liposomal DDS that releases therapeutic doses of an anticancer drug in response to external stimulus. Earlier, we introduced degradable plasmon resonant liposomes. These constructs, obtained by reducing gold on the liposome surface, facilitate spatial and temporal release of drugs upon laser light illumination that ultimately induces an increase in temperature. In this work, plasmon resonant liposomes have been developed to stably encapsulate and retain doxorubicin at physiological conditions represented by isotonic saline at 37 °C and pH 7.4. Subsequently, they are stimulated to release contents either by a 5 °C increase in temperature or by laser illumination (760 nm and 88 mW/cm2 power density). Successful development of degradable plasmon resonant liposomes responsive to near-infrared light or moderate hyperthermia can provide a new delivery method for multiple lipophilic and hydrophilic drugs with pharmacokinetic profiles that limit clinical utility.

KW - drug delivery

KW - Liposomes

KW - nanomedicine

KW - plasmon resonance

UR - http://www.scopus.com/inward/record.url?scp=84931858265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931858265&partnerID=8YFLogxK

U2 - 10.1117/12.2080485

DO - 10.1117/12.2080485

M3 - Conference contribution

AN - SCOPUS:84931858265

SN - 9781628414288

VL - 9338

BT - Progress in Biomedical Optics and Imaging - Proceedings of SPIE

PB - SPIE

ER -